Peter Voorhees, MD of @LevineCancer discusses the depth of response to dara, lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients with transplant-eligible newly diagnosed multiple myeloma: GRIFFIN study update.
Advertisement